Proparacaine Hydrochloride

Manufacturer
MWI | Akorn Operating Company LLC | Akorn
Effective date
2022-02-04
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 20:39:56

Label at a glance#

ProductProparacaine Hydrochloride
Active ingredientProparacaine Hydrochloride
Label structure13 sections

Indications and uses

Proparacaine Hydrochloride Ophthalmic Solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical...

Dosage and administration

Deep anesthesia as in cataract extraction:   Instill 1 drop to the eye every 5 to 10 minutes for 5 to 7 doses. Removal of sutures:   Instill 1 or 2 drops to the eye 2 or 3 minutes before removal of stitches. Removal of foreign bodies:   Instill 1 or 2 drops to the eye prior to operating. Tonometry:   Instill 1 or 2 drops to the eye immediately before measurement.

Storage and handling

Refrigerate at 2° to 8°C (36° to 46°F). Keep bottle tightly closed. Store in carton until empty to protect from light. If solution shows more than a faint yellow color, it should not be used. WARNING — KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. apexa™ Manufactured by: Akorn Inc. Lake Forest, IL 60045 Distributed by: MWI Boise, ID 83705 MWPR00N         Rev. 08/14

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Ophthalmic Solution, USP
0.5% Sterile

Rx Only

DESCRIPTION:

DESCRIPTION SECTION

Proparacaine Hydrochloride Ophthalmic Solution USP, 0.5% is a local anesthetic for ophthalmic instillation. Each mL of sterile, aqueous solution contains: Active: Proparacaine Hydrochloride 5 mg (0.5%). Inactives: Glycerin as a stabilizer, Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (3.5 to 6.0), and Water for Injection. Preservative: Benzalkonium Chloride 0.1 mg (0.01%).

Proparacaine hydrochloride is designed chemically as 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate monohydrochloride. The active ingredient is represented by the structural formula:

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Proparacaine Hydrochloride Ophthalmic Solution is a rapid acting local anesthetic suitable for ophthalmic use. With a single drop, the onset of anesthesia begins within 30 seconds and persists for 15 minutes or longer.

The main site of anesthetic action is the nerve cell membrane where proparacaine interferes with the large transient increase in the membrane permeability to sodium ions that is normally produced by a slight depolarization of the membrane. As the anesthetic action progressively develops in a nerve, the threshold for electrical stimulation gradually increases and the safety factor for conduction decreases; when this action is sufficiently well developed, block of conduction is produced.

The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability by closing the pores through which the ions migrate in the lipid layer of the nerve cell membrane. This limitation prevents the fundamental change necessary for the generation of the action potential.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Proparacaine Hydrochloride Ophthalmic Solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical anesthetic prior to surgical operations such as cataract extraction.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

This preparation is contraindicated in patients with known hypersensitivity to any component of the solution.

WARNINGS:

WARNINGS SECTION

NOT FOR INJECTION. FOR TOPICAL OPHTHALMIC USE ONLY.

Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification with accompanying loss of vision.

PRECAUTIONS:

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Proparacaine should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity of proparacaine is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, it should be borne in mind that systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.

Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off. Do not touch dropper tip to any surface as this may contaminate the solution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.

Pregnancy: Teratogenic Effects

PREGNANCY SECTION

Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with Proparacaine Hydrochloride Ophthalmic Solution. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Controlled clinical studies have not been performed with Proparacaine Hydrochloride Ophthalmic Solution to establish safety and effectiveness in pediatric patients; however, the literature cites the use of proparacaine hydrochloride as a topical ophthalmic anesthetic agent in pediatric patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Pupillary dilatation or cycloplegic effects have rarely been observed with proparacaine hydrochloride. The drug appears to be safe for use in patients sensitive to other local anesthetics, but local or systemic sensitivity occasionally occurs. Instillation of proparacaine in the eye at recommended concentration and dosage usually produces little or no initial irritation, stinging, burning, conjunctival redness, lacrimation or increased winking. However, some local irritation and stinging may occur several hours after the instillation.

Rarely, a severe, immediate-type, apparently hyperallergic corneal reaction may occur which includes acute, intense and diffuse epithelial keratitis; a gray, ground-glass appearance; sloughing of large areas of necrotic epithelium; corneal filaments and, sometimes, iritis with descemetitis.

Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.

Softening and erosion of the corneal epithelium and conjunctival congestion and hemorrhage have been reported.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Deep anesthesia as in cataract extraction:

  • Instill 1 drop to the eye every 5 to 10 minutes for 5 to 7 doses.

Removal of sutures:

  • Instill 1 or 2 drops to the eye 2 or 3 minutes before removal of stitches.

Removal of foreign bodies:

  • Instill 1 or 2 drops to the eye prior to operating.

Tonometry:

  • Instill 1 or 2 drops to the eye immediately before measurement.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Proparacaine Hydrochloride Ophthalmic Solution USP, 0.5% is supplied as a sterile solution in 15 mL plastic dropper bottles — NDC 13985-611-15

STORAGE:

STORAGE AND HANDLING SECTION

Refrigerate at 2° to 8°C (36° to 46°F). Keep bottle tightly closed. Store in carton until empty to protect from light. If solution shows more than a faint yellow color, it should not be used.

WARNING — KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

apexa™
Manufactured by: Akorn Inc.
Lake Forest, IL 60045

Distributed by: MWI
Boise, ID 83705

MWPR00N         Rev. 08/14

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 13985-611-15

Proparacaine Hydrochloride

Ophthalmic Solution, USP 0.5%

FOR TOPICAL

OPHTHALMIC USE ONLY.

NOT FOR INJECTION.

Apexa logo STERILE

Rx Only

AP 704013 15 mL

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 13985-611-15

Proparacaine

Hydrochloride

Ophthalmic

Solution

USP, 0.5%

FOR TOPICAL

OPHTHALMIC USE ONLY.

NOT FOR INJECTION.

STERILE

Rx Only

Apexa logo

AP 704013 15 mL

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1191013proparacaine HCl 0.5 % Ophthalmic SolutionPSN4
1191013proparacaine hydrochloride 5 MG/ML Ophthalmic SolutionSCD4
1191013proparacaine hydrochloride 0.5 % Ophthalmic SolutionSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PROPARACAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9ba0893a-4390-4124-b66b-ffd4f2b29a0eProduct name220260305

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
13985-611-152024-01-30C16284748780-11030e365-3ed9-111a-e063-dadaa90a10e2apexa™ Proparacaine Hydrochloride

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
13985-611-15Proparacaine Hydrochloride15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS154
13985-611-15Proparacaine Hydrochloride1 in 1 CARTONSOLUTION/ DROPS14

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
13985-611PROPARACAINE HYDROCHLORIDE SOLUTION/ DROPS [MWI]4Legacy NDC, 2 package rows20220205_66e8723a-620c-42ed-a43e-cfa30014e1dc.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Proparacaine HydrochlorideACTIVE INGREDIENTU96OL57GOY1
ProparacaineACTIVE MOIETYB4OB0JHI1X1
Benzalkonium ChlorideINACTIVE INGREDIENTF5UM2KM3W71
GlycerinINACTIVE INGREDIENTPDC6A3C0OX1
Hydrochloric AcidINACTIVE INGREDIENTQTT17582CB1
Sodium HydroxideINACTIVE INGREDIENT55X04QC32I1
WaterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
13985-61113985-611-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 421 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
GlycerinGLYCERINPDC6A3C0OXSPRAY, METERED / NASAL13 mgExact identifier — unii candidate
75 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSPONGE / TOPICAL2 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-ARTERIAL840 mgExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IFILM, SOLUBLE / BUCCAL5 mgExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ORAL125 mgExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS5 mgExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION / OPHTHALMIC1 mgExact identifier — unii candidate
24 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / RESPIRATORY (INHALATION)8 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION / AURICULAR (OTIC)63.64 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ITABLET / ORAL10 mgExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION/ DROPS / AURICULAR (OTIC)25 mgExact identifier — unii candidate
75 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXCLOTH / TOPICAL0.05 mg/mgExact identifier — unii candidate
75 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXDOUCHE / VAGINAL1 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRABURSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBTABLET / ORAL2.32 mgExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSYSTEM / IONTOPHORESIS168.1 mgExact identifier — unii candidate
75 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY / NASAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGRANULE, FOR SUSPENSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXINJECTION, SUSPENSION / SUBCUTANEOUS1.6 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSUSPENSION, EXTENDED RELEASE / ORAL2000 mgExact identifier — unii candidate
75 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / TOPICAL0.01 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXAEROSOL, FOAM / TOPICAL21 mgExact identifier — unii candidate
75 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSPRAY, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / TRANSDERMAL472 mgExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXGEL / TRANSDERMAL500 mgExact identifier — unii candidate
75 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION / TOPICAL1971 mgExact identifier — unii candidate
75 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXCAPSULE / ORAL3487 mgExact identifier — unii candidate
75 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXINJECTION / INTRADERMAL1.6 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IEMULSION / OPHTHALMIC0.02 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ICAPSULE / ORAL60 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / DENTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSPRAY / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR5.4 mgExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IDISC / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION / OPHTHALMIC6 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / DENTALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii candidate
148 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSPRAY / NASAL10 mlExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040277-001PROPARACAINE HYDROCHLORIDEPROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A040277-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1684e616aacf4f…
2026-08-18 06:07:402026-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1631067a03dcf5…
2025-08-23 18:47 UTC2025-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-166a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-162680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-165bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-1679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-161e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-168072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-164b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-1674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-1687673890dc5c…
2021-03-12 10:30 UTC2021-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-165aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-168869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163f01610625f2…
2019-09-15 20:21 UTC2019-09A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16b00525d2431f…
2019-07-19 19:46 UTC2019-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-166a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-161c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-16a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICAT2000-03-169b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163f0d92c62455…
2023-05-13 08:27 UTC2023-05A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16053a50430f4f…
2023-01-26 05:58 UTC2023-01A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-163a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040277-001PROPARACAINE HYDROCHLORIDE0.5%SOLUTION/DROPS / OPHTHALMICATRS2000-03-16f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A040277-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A040277-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040277-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040277-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040277-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040277-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040277-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040277-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040277-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040277-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040277-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040277-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040277-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040277-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040277-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040277-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040277-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040277-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040277-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040277-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040277-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040277-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040277-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A040277-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040277-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040277-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040277-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A040277-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A040277-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040277-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040277-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040277-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040277-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040277-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040277-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040277-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A040277-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A040277-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040277-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040277-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
38a62501-a39a-435e-8623-6417beaf55ca66e8723a-620c-42ed-a43e-cfa30014e1dc2022-02-04Warnings, Adverse reactionsExact identifier
spl id: 38a62501-a39a-435e-8623-6417beaf55ca
spl set id: 66e8723a-620c-42ed-a43e-cfa30014e1dc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.